
Crystalys Therapeutics CEO Dr James Mackay explains at BIO 2026 that gout remains an underserved therapeutic are and represents a compelling drug development target due to its unmet need and simple biology.
James Mackay, Ph.D., President and Chief Executive Officer is a co-founder of Crystalys Therapeutics. James has over 40 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. Prior to founding Crystalys, he was CEO and co-founder of Aristea Therapeutics and President and CEO of Ardea Biosciences. Prior to Ardea, James held senior executive positions over a 30 year period at AstraZeneca where he led the development and commercialization of drugs across a range of therapy areas and managed significant global functional departments. James plays a pivotal role in the San Diego innovation ecosystem holds a BS in Genetics and Ph.D. in Medical Genetics from Aberdeen University, Scotland.

Crystalys Therapeutics CEO Dr James Mackay explains at BIO 2026 that gout remains an underserved therapeutic are and represents a compelling drug development target due to its unmet need and simple biology.